May aid in the diagnosis of acute Epstein-Barr virus (EBV) infection and EBV reactivation in conjunction with other serologic studies. Molecular tests are preferred to detect EBV reactivation. Not a stand-alone test.
Semi-Quantitative Chemiluminescent Immunoassay
New York DOH Approval Status
Serum Separator Tube (SST).
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens.
Contaminated, heat-inactivated or grossly hemolyzed specimens.
Label specimens plainly as "acute" or "convalescent."
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Effective February 19, 2013
8.9 U/mL or less: Not Detected
9.0-10.9 U/mL: Indeterminate - Repeat testing in 10-14 days may be helpful.
11.0 U/mL or greater: Detected
EBV EA-D values obtained with different manufacturers' assay methods may not be used interchangeably. The magnitude of the reported EBV EA-D level cannot be correlated to an endpoint titer.
|Component Test Code*||Component Chart Name||LOINC|
|0050225||EBV Antibody to Early (D) Antigen IgG||50969-5|
- EA-D IgG Ab
- EAD Ab
- EBNA Antibody
- EBNA to EA-D
- EBV Antibody to Early D Antigen
- EBV Nuclear Antibody